anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lidocaine
Trial phase: Not Applicable
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Intravenous lidocaine for neuropathic pain

lidocaine: intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
Eligibility criteria:
Inclusion Criteria:

Chronic Regional Pain Syndrome diagnostic criteria by the Work Safe BC. vi

Exclusion Criteria:

History of Substance abuse
Other Medications: CRPS patients are expected to be treated for chronic pain, whether the current treatment regimen interferes with sensory motor testing will be determined on a case by case basis.
Coronary Artery Disease (CAD): unstable
Congestive Heart Failure (CHF): unstable
Heart Arrhythmia: symptomatic
Chronic Obstructive Pulmonary Disease (COPD)
Lidocaine Allergy
Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I disorders include depression, anxiety disorders, bipolar disorder, ADHD, and schizophrenia. Axis II: borderline personality disorder, schizotypal personality disorder, antisocial personality disorder, and mild mental retardation.
Presence of Contraindications for MRI
Presence of electronically, magnetically, and mechanically activated implants
Electronically, magnetically, and mechanically activated implants
Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators
Cardiac pacemakers
Metallic splinters in the eye
Ferromagnetic haemostatic clips in the central nervous system (CNS)
Claustrophobia
Pregnancy
Intervention: Sitagliptin phosphate monohydrate
Trial phase: Not Applicable
SMILES: NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: The first group will be started on 100 mg sitagliptin daily for 12 weeks

Januvia (Sitagliptin) 100 mg: The first group will be started on 100 mg sitagliptin daily for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Males or females with age 20-75 years inclusive.
Type 2 diabetes
Males and Females BMI > 30
Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study.
BP under control -No change required to BP medications
HbA1c > 7%

Exclusion Criteria:

Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
Pregnancy
Hepatic disease (abnormal LFT's),Renal impairment (serum creatinine > 1.5),
Participation in any other concurrent clinical trial
Any other life-threatening, non-cardiac disease,
Uncontrolled hypertension (BP > 160/100 mm of Hg)
Congestive Heart Failure
Use of an investigational agent or therapeutic regimen within 30 days of study
Subjects on Exenatide, incretin or insulin therapy
Intervention: Scopolamine
Trial phase: Not Applicable
ATC code: A04AD01 | A04AD51 | N05CM05 | S01FA02
SMILES: CN1C2CC(OC(=O)C(CO)c3ccccc3)CC1C1OC12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 58
Group description: Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.

Scopolamine + Emend (Aprepitant): 1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
Eligibility criteria:
Inclusion Criteria:

Patient must be between 18 and 65 years of age.
Patient's ASA (American Society of Anesthesiologist) class must be between 1 and 3.
If patient is currently on oral contraceptive to prevent pregnancy, she must be willing to use a back up form of birth control for one month post study.

Patient must have 1 FACTOR to qualify

Female Sex
History of PONV
Motion Sickness
Non-Smoker
Intended Use of Post Operative Opioids

Exclusion Criteria:

Patients with a history of vomiting due to middle ear infection, nervous system disorder, or any other condition.
The surgical procedure is less than 1 hour.
The patient is pregnant or breast feeding.
The patient has taken antiemetic medication in previous 24 hours.
Patients with narrow-angle glaucoma.
Allergy to belladonna alkaloids.
Hypersensitivity to barbiturates.

Patient taking any of the following medications:

Orap
Seldane
Hismanal
Propulsid
Phenytoin
Phenothiazines
Tricyclic Antidepressants
Meperidine
Tolbutamide
Aluminum and Magnesium Trisilicate-containing Antacids
Anti-Cholinergics
Coumadin
Male patients with prostate hypertrophy.
Patients with severe hepatic disease.
Patients on Chemotherapy and taking Aprepitant.
Patients with fever.
Patients with sepsis.
Intervention: Azacitidine
Trial phase: Not Applicable
ATC code: L01BC07
SMILES: Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
Eligibility criteria:
Inclusion Criteria:

Potential candidate for HCT.
Histologically confirmed diagnosis by pathologic review of previous diagnosis of high-risk myelodysplastic syndrome (MDS): International Prognostic Scoring System (IPSS) > 1 or AML-MDS or treatment related MDS.
Serum bilirubin levels ≤1.5 times the upper limit of the normal (ULN) range for the laboratory. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis; Serum glutamic-oxaloacetic transaminase (SGOT) [aspartate aminotransferase (AST)] or serum glutamic pyruvic transaminase (SGPT) [alanine aminotransferase (ALT)] levels ≤2 x ULN.
Serum creatinine levels ≤1.5 x ULN
Karnofsky performance status greater or equal to 70%
Signed informed consent form in accordance with institutional policies

Exclusion Criteria:

Known or suspected hypersensitivity to Vidaza or mannitol
Pregnant or lactating women
Human immunodeficiency virus (HIV) or seropositive, confirmed by nucleic acid amplification testing (NAT)
Active central nervous system (CNS) malignancy
Active infection
History or presence of primary hepatoma
Intervention: Azelastine Hydrochloride
Trial phase: Phase 3
SMILES: CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 152
Group description: azelastine Hcl nasal spray one spray per nostril two times a day
Eligibility criteria:
Inclusion Criteria:

Male and female subjects 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis
Must be in generally good health
Must meet minimum symptom requirements, as specified in the protocol.
Must be willing and able to provide informed consent and to participate in all study procedures
Positive skin test to a prevalent Texas Mountain Cedar allergen

Exclusion Criteria:

On Focused Nasal Examination, the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation (Grade 1b - 4) at either the screening visit or randomization visit will disqualify the subject from the study.
Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal structural abnormalities.
Nasal surgery or sinus surgery within the previous year.
Chronic sinusitis - more than 3 episodes per year
Planned travel outside of the study area during the study period
The use of any investigational drug within 30 days prior to Day screening. No investigational products are permitted for use during the conduct of this study
Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate
Women who are pregnant or nursing
Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception* see section 6.1.1
Respiratory Tract Infections within 14 days prior to Day screening
Respiratory Tract Infections requiring antibiotic treatment 14 days prior to screening
Asthma (with the exception of mild, intermittent asthma). Subjects with mild, intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
Significant pulmonary disease including COPD
Clinically significant arrhythmia or symptomatic cardiac conditions
A known history of alcohol or drug abuse within the last 2 years
Existence of any surgical or medical condition or physical or laboratory findings, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.
Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
Intervention: FLUTICASONE PROPIONATE
Trial phase: Phase 3
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 151
Group description: fluticasone propionate nasal spray one spray per nostril two times a day
Eligibility criteria:
Inclusion Criteria:

Male and female subjects 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis
Must be in generally good health
Must meet minimum symptom requirements, as specified in the protocol.
Must be willing and able to provide informed consent and to participate in all study procedures
Positive skin test to a prevalent Texas Mountain Cedar allergen

Exclusion Criteria:

On Focused Nasal Examination, the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation (Grade 1b - 4) at either the screening visit or randomization visit will disqualify the subject from the study.
Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal structural abnormalities.
Nasal surgery or sinus surgery within the previous year.
Chronic sinusitis - more than 3 episodes per year
Planned travel outside of the study area during the study period
The use of any investigational drug within 30 days prior to Day screening. No investigational products are permitted for use during the conduct of this study
Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate
Women who are pregnant or nursing
Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception* see section 6.1.1
Respiratory Tract Infections within 14 days prior to Day screening
Respiratory Tract Infections requiring antibiotic treatment 14 days prior to screening
Asthma (with the exception of mild, intermittent asthma). Subjects with mild, intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
Significant pulmonary disease including COPD
Clinically significant arrhythmia or symptomatic cardiac conditions
A known history of alcohol or drug abuse within the last 2 years
Existence of any surgical or medical condition or physical or laboratory findings, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.
Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
Intervention: Omeprazole
Trial phase: Phase 4
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 143
Group description: Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
Eligibility criteria:
Inclusion Criteria:

Prior to the run-in period, a history of heartburn or acid regurgitation for 3 months or longer or any history of EE;
Prior to the run-in period, nighttime heartburn averaging at least 2 or 3 times per week;
Prior to the run-in period, a history of sleep disturbances associated with GERD for 1 month or more;

Exclusion Criteria:

Any condition other than GERD that is either the primary cause of, or a significant contributor to, the patient's sleep disturbance
Sleep medication (including over-the-counter), antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable (either in dose or regularity) for at least 3 months or is not expected to remain stable during the patient's participation in the study. Patients on a stable regimen, whose regimen is also expected to remain stable throughout the study, are eligible for participation;
Proton Pump Inhibitor (PPI) use within 1 week prior to Screening. The only allowable acid modifying rescue medication is GELUSIL® during the run-in period. Only study medication and rescue medication (GELUSIL®) is allowed during the treatment period for treatment of acid mediated symptoms
Intervention: Azelastine Hydrochloride
Trial phase: Phase 3
SMILES: CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 266
Group description: 0.15% Azelastine Hydrochloride Nasal Spray/2 sprays per nostril once daily for 14 days
Eligibility criteria:
Inclusion Criteria:

Male and Female patients 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis.
Must be in generally good health
Must meet minimum symptom requirements, as specified in the protocol
Must be willing and able to provide informed consent and to participate in all study procedures
Positive skin test to a prevalent Texas Mountain Cedar allergen

Exclusion Criteria:

On Focused Nasal Examination, the presence of any nasal mucosal erosion, nasal ulceration, or nasal septal perforation at either the screening visit or randomization visit will disqualify the subject from the study.
Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal structural abnormalities.
Nasal surgery or sinus surgery within the previous year.
Chronic sinusitis - more than 3 episodes per year
Planned travel outside of the study area during the study period
The use of any investigational drug within 30 days prior to Screening. No investigational products are permitted for use during the conduct of this study
Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
Women who are pregnant or nursing
Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception
Respiratory Tract Infections within 14 days prior to screening
Respiratory Tract Infections requiring antibiotic treatment 14 days prior to screening
Asthma (with the exception of mild, intermittent asthma). Subjects with mild, intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
Significant pulmonary disease including COPD
Clinically significant arrhythmia or symptomatic cardiac conditions
A known history of alcohol or drug abuse within the last 2 years
Existence of any surgical or medical condition or physical or laboratory findings, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.
Clinically relevant abnormal physical findings which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
Intervention: Adapalene
Trial phase: Phase 4
ATC code: D10AD03 | D10AD53
SMILES: COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Gel, 0.3%, 2g, once daily for 30 days
Eligibility criteria:
Inclusion Criteria:

Male or female 18 to 35 years of age
Clinical diagnosis of acne vulgaris
Minimum of 20 Inflammatory
Minimum of 20 Non-inflammatory lesions
The subject has a body weight between 45 and 100 kg, and a Body Mass Index (BMI) between 18 and 30Kg/m2

Exclusion Criteria:

More than 1 nodule or any cyst on the face (excluding the nose)
Acne conglobata, acne fulminans, secondary acne or severe acne
Underlying diseases or other dermatological conditions that require the use of interfering topical or systemic therapy
Pregnant or nursing or planning a pregnancy
Surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the drug
Known allergies to any of the ingredients of the study medication
History of alcohol or drug abuse or positive test results for any drug abuse
Positive test results for hepatitis B surface antigen (HBs-Ag), hepatitis C virus (HCV) or human immunodeficiency virus antibodies (HIV Ab)
Use of prohibited medications prior to the study unless appropriate washout period is documented
Intervention: Adapalene
Trial phase: Phase 4
ATC code: D10AD03 | D10AD53
SMILES: COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Gel, 0.1%, 2g, once daily for 30 days
Eligibility criteria:
Inclusion Criteria:

Male or female 18 to 35 years of age
Clinical diagnosis of acne vulgaris
Minimum of 20 Inflammatory
Minimum of 20 Non-inflammatory lesions
The subject has a body weight between 45 and 100 kg, and a Body Mass Index (BMI) between 18 and 30Kg/m2

Exclusion Criteria:

More than 1 nodule or any cyst on the face (excluding the nose)
Acne conglobata, acne fulminans, secondary acne or severe acne
Underlying diseases or other dermatological conditions that require the use of interfering topical or systemic therapy
Pregnant or nursing or planning a pregnancy
Surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the drug
Known allergies to any of the ingredients of the study medication
History of alcohol or drug abuse or positive test results for any drug abuse
Positive test results for hepatitis B surface antigen (HBs-Ag), hepatitis C virus (HCV) or human immunodeficiency virus antibodies (HIV Ab)
Use of prohibited medications prior to the study unless appropriate washout period is documented
Intervention: Mitomycin
Trial phase: Phase 1 | Phase 2
ATC code: L01DC03
SMILES: [H][C@]12N[C@@]1([H])CN1C3=C(C(=O)C(N)=C(C)C3=O)[C@@H](COC(N)=O)[C@]12OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: MMC therapy alone (n=10)

MMC: MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
Eligibility criteria:
Inclusion Criteria:

glaucoma
undergoing trabeculectomy
21 years of age or older

Exclusion Criteria:

pregnancy or lactation
any condition the investigator believes would impose a significant hazard to the patient if investigational therapy were initiated
history of ocular surface disease
cataract surgery in the past 6 months
history of active inflammatory, infectious or idiopathic keratitis
Intervention: Raltegravir
Trial phase: Not Applicable
ATC code: J05AJ01 | J05AR16 | J05AX08
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
Eligibility criteria:
Inclusion Criteria:

willing to sign consent form
no known GI pathology
no anticipated antiretroviral therapy adjustments or changes
males & females between the ages of 18 & 50 years
no active opportunistic infections (OI) or therapy for OI within 30 days of entry
can be on secondary prophylaxis with a history of AIDS defining illness
per standard of care requirements, all females of child-bearing potential must agree to use barrier methods to prevent pregnancy or be abstinent from activity while on study

Exclusion Criteria:

abnormal coagulation parameters (PT > or equal to 1.2 ULN)
thrombocytopenia (platelet count < 50,000 within 6 weeks)
contra-indications to upper endoscopy or conscious sedation
anemia (> or equal to grade 1)
aspirin, ibuprofen, warfarin or other agents that interfere with the coagulation cascade are prohibited within 1 week of endoscopy
Intervention: Prednisolone
Trial phase: Phase 4
ATC code: A01AC04 | A01AC54 | A07EA01 | C05AA04 | D07AA03 | D07BA01 | D07CA03 | D07XA02 | H02AB06 | R01AD02 | R01AD52 | S01BA04 | S01BB02 | S01CA02 | S01CB02 | S02BA03 | S02CA01 | S03BA02 | S03CA02 | V03AB05
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: prednisolone: 40mg of prednisolone once a day for 14 days
Eligibility criteria:
Inclusion Criteria:

for severe asthmatics:

Physician diagnosis of asthma
Aged 18 - 70
Non-smokers or ex-smokers with less than 5 pack/year history
Major characteristics (at least one of the following criteria)
Treatment with continuous or near continuous (>50% of year) oral corticosteroids
Requirement for treatment with high dose inhaled corticosteroids (ICS)

Minor characteristics (at least 2 out of the following)

Requirement for daily treatment with a controller medication in addition to ICS e.g. LABA, theophylline, leukotriene antagonist
Asthma symptoms requiring SABA on a daily or near daily basis
Persistent airways obstruction (FEV1 <80% predicted, diurnal PEF variation >20%)
One or more emergency care visits for asthma per year
3 or more steroid "bursts" per year
Prompt deterioration with ≤ 25% reduction in oral or ICS
Near fatal asthma event in the past

for moderately-severe asthma:

Physician diagnosis of asthma
Aged 18 - 70
Non-smokers or ex-smokers with less than 5 pack/year history
Less than 2 courses of prednisolone per year
Taking up to 2000 mcg of inhaled corticosteroid (BDP equivalent) per day
Stable asthma for at least 6 months prior to enrollment

Exclusion Criteria:

Current smokers, or less than 3 years since quitting smoking
Less than 4 weeks from an exacerbation
Diabetes
Active peptic ulceration
Previous history of psychiatric disturbances on high dose prednisolone
On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin
Concomitant anti-IgE therapy
Pregnancy
Intervention: Celecoxib
Trial phase: Phase 3
ATC code: C08CA51 | G01AE10 | L01XX33 | M01AH01 | N02AJ16
SMILES: Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 396
Group description: 200 mg capsules two times a day (BID) for 6 weeks
Eligibility criteria:
Inclusion Criteria:

The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used

Exclusion Criteria:

The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)